메뉴 건너뛰기




Volumn 15, Issue 3, 1997, Pages 273-284

The role of GnRH agonists plus add-back therapy in the treatment of endometriosis

Author keywords

Add back; Endometriosis; GnRH agonist; Pelvic pain

Indexed keywords

BUSERELIN; CALCIUM; CONJUGATED ESTROGEN; DANAZOL; ESTROGEN; ETIDRONIC ACID; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; HISTRELIN; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; NAFARELIN; NORETHISTERONE; NORETHISTERONE ACETATE; PARATHYROID HORMONE; SALCATONIN; TRIPTORELIN;

EID: 0030690975     PISSN: 07348630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1068757     Document Type: Review
Times cited : (13)

References (85)
  • 1
    • 0024552429 scopus 로고
    • Clinical epidemiology of endometriosis and infertility
    • Guzick DS: Clinical epidemiology of endometriosis and infertility. Obstet Gynecol Clin No Am 16:43-59, 1989
    • (1989) Obstet Gynecol Clin No Am , vol.16 , pp. 43-59
    • Guzick, D.S.1
  • 2
    • 0028964109 scopus 로고
    • Hormonal regulation of endometriosis and the rationales and effects of gonadotropin-releasing hormone agonist treatment: A review
    • Bergqvist IA: Hormonal regulation of endometriosis and the rationales and effects of gonadotropin-releasing hormone agonist treatment: a review. Hum Reprod 10:446-452, 1995
    • (1995) Hum Reprod , vol.10 , pp. 446-452
    • Bergqvist, I.A.1
  • 3
    • 0026098581 scopus 로고
    • Gonadotropin-releasing hormone and its analogues
    • Conn PM, Crowley WFJ: Gonadotropin-releasing hormone and its analogues. N Engl J Med 324:93, 1991
    • (1991) N Engl J Med , vol.324 , pp. 93
    • Conn, P.M.1    Crowley, W.F.J.2
  • 4
    • 0024231955 scopus 로고
    • LHRH analogues: Their clinical physiology and delivery systems
    • Fraser HM: LHRH analogues: their clinical physiology and delivery systems. Baillieres Clin Obstet Gynecol 2:639, 1988
    • (1988) Baillieres Clin Obstet Gynecol , vol.2 , pp. 639
    • Fraser, H.M.1
  • 5
    • 0022665939 scopus 로고
    • Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective
    • Karten MJ, Rivier JE: Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 7:44, 1986
    • (1986) Endocr Rev , vol.7 , pp. 44
    • Karten, M.J.1    Rivier, J.E.2
  • 6
    • 0015251023 scopus 로고
    • Primary structure of ovine hypothalamic luteinizing hormone factor (LRF)
    • Burgus R, Butcher M, Amoss M, et al: Primary structure of ovine hypothalamic luteinizing hormone factor (LRF). Proc Natl Acad Sci USA 69:278, 1972
    • (1972) Proc Natl Acad Sci USA , vol.69 , pp. 278
    • Burgus, R.1    Butcher, M.2    Amoss, M.3
  • 7
    • 0015231127 scopus 로고
    • Structure of the porcine LH- And FSH-releasing hormone: I. the proposed amino acid sequence
    • Matsuo H, Baba Y, Nair RM, et al: Structure of the porcine LH- and FSH-releasing hormone: I. The proposed amino acid sequence. Biochem Biophis Res Commun 43:1334, 1971
    • (1971) Biochem Biophis Res Commun , vol.43 , pp. 1334
    • Matsuo, H.1    Baba, Y.2    Nair, R.M.3
  • 8
    • 0018848036 scopus 로고
    • The neuroendocrine control of the menstrual cycle
    • Knobil E: The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res 36:53-88, 1980
    • (1980) Recent Prog Horm Res , vol.36 , pp. 53-88
    • Knobil, E.1
  • 9
    • 0020532179 scopus 로고
    • Clinical applications of LHRH and its analogues
    • Sandow J: Clinical applications of LHRH and its analogues. Clin Endocrinol (Oxf) 18:571, 1983
    • (1983) Clin Endocrinol (Oxf) , vol.18 , pp. 571
    • Sandow, J.1
  • 10
    • 17144467338 scopus 로고
    • Antifertility effects of luteinizing hormone-releasing hormone (LHRH) agonists
    • Labrie F, Belanger A, Kelly PA, et al: Antifertility effects of luteinizing hormone-releasing hormone (LHRH) agonists. Prog Clin Biol Res 74:273, 1981
    • (1981) Prog Clin Biol Res , vol.74 , pp. 273
    • Labrie, F.1    Belanger, A.2    Kelly, P.A.3
  • 11
    • 0019943192 scopus 로고
    • Danazol in the treatment of endometriosis: Analysis of 100 cases with a 4-year follow-up
    • Barbieri RL, Evans S, Kistner RW: Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 36:737-747, 1982
    • (1982) Fertil Steril , vol.36 , pp. 737-747
    • Barbieri, R.L.1    Evans, S.2    Kistner, R.W.3
  • 12
    • 0021949970 scopus 로고
    • Treatment of endometriosis with danazol: Report of a six year prospective study
    • Buttram VC, Reiter RC, Ward S: Treatment of endometriosis with danazol: report of a six year prospective study. Fertil Steril 43:353, 1985
    • (1985) Fertil Steril , vol.43 , pp. 353
    • Buttram, V.C.1    Reiter, R.C.2    Ward, S.3
  • 13
    • 0024204055 scopus 로고
    • Gonadotropin releasing hormone (GnRH) agonists in the management of endometriosis: A review
    • Henzl MH: Gonadotropin releasing hormone (GnRH) agonists in the management of endometriosis: a review. Clin Obstet Gynecol 31:840-856, 1988
    • (1988) Clin Obstet Gynecol , vol.31 , pp. 840-856
    • Henzl, M.H.1
  • 14
    • 0023864757 scopus 로고
    • Administration of nasal nafarelin as compared with oral danazol for endometriosis
    • Henzl MR, Corson SL, Moghissi K, et al: Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 318:485-489, 1988
    • (1988) N Engl J Med , vol.318 , pp. 485-489
    • Henzl, M.R.1    Corson, S.L.2    Moghissi, K.3
  • 15
    • 0022034741 scopus 로고
    • Revised American Fertility Society Classification of endometriosis
    • The American Fertility Society: Revised American Fertility Society Classification of endometriosis. Fertil Steril 43:351, 1985
    • (1985) Fertil Steril , vol.43 , pp. 351
  • 16
    • 0026576010 scopus 로고
    • Nafarelin for endometriosis: A large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up
    • Nafarelin European Endometriosis Trial Group (NEET): Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up. Fertil Steril 57:514-522, 1992
    • (1992) Fertil Steril , vol.57 , pp. 514-522
  • 17
    • 0025763359 scopus 로고
    • A comparative treatment trial of endometriosis using the gonadotropin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol
    • Fraser IS, Shearman RP, Jansen RP, Sutherland PD: A comparative treatment trial of endometriosis using the gonadotropin-releasing hormone agonist, nafarelin, and the synthetic steroid, danazol. Aust N Z J Obstet Gynaecol 31:158-163, 1991
    • (1991) Aust N Z J Obstet Gynaecol , vol.31 , pp. 158-163
    • Fraser, I.S.1    Shearman, R.P.2    Jansen, R.P.3    Sutherland, P.D.4
  • 18
    • 0342684678 scopus 로고
    • A comparative study between buserelin and danazol in the treatment of endometriosis
    • Matta MH, Shaw RW: A comparative study between buserelin and danazol in the treatment of endometriosis. Br J Clin Pract 41(suppl 48):64, 1987
    • (1987) Br J Clin Pract , vol.41 , Issue.SUPPL. 48 , pp. 64
    • Matta, M.H.1    Shaw, R.W.2
  • 19
    • 0024418946 scopus 로고
    • Buserelin versus danazol in the treatment of endometriosis-associated infertility
    • Fedele L, Bianchi S, Arcaini L, et al: Buserelin versus danazol in the treatment of endometriosis-associated infertility. Am J Obstet Gynecol 161:871-876, 1989
    • (1989) Am J Obstet Gynecol , vol.161 , pp. 871-876
    • Fedele, L.1    Bianchi, S.2    Arcaini, L.3
  • 20
    • 0025138807 scopus 로고
    • A comparison of the efficiency and safety of buserelin vs danazol in the treatment of endometriosis
    • Protocol 310 Study Group
    • Dawood MY, Spellacy WN, Dmowski WP, et al: A comparison of the efficiency and safety of buserelin vs danazol in the treatment of endometriosis. Protocol 310 Study Group. Prog Clin Biol Res 323:253-267, 1990
    • (1990) Prog Clin Biol Res , vol.323 , pp. 253-267
    • Dawood, M.Y.1    Spellacy, W.N.2    Dmowski, W.P.3
  • 21
    • 0025005019 scopus 로고
    • Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized placebo-controlled double-blind study
    • Dlugi AM, Miller JD, Knittle J: Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized placebo-controlled double-blind study. Fertil Steril 54:419-427, 1990
    • (1990) Fertil Steril , vol.54 , pp. 419-427
    • Dlugi, A.M.1    Miller, J.D.2    Knittle, J.3
  • 22
    • 0026446444 scopus 로고
    • Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: A multicenter double-blind randomized clinical trial. I. Efficacy results
    • Wheeler JM, Knittle JD, Miller JD, Lupron Endometriosis Study Group: Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter double-blind randomized clinical trial. I. Efficacy results. Am J Obstet Gynecol 167:1367-1371, 1992
    • (1992) Am J Obstet Gynecol , vol.167 , pp. 1367-1371
    • Wheeler, J.M.1    Knittle, J.D.2    Miller, J.D.3
  • 23
    • 0027279278 scopus 로고
    • Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: A multicenter double-blind randomized clinical trial. II. Assessment of safety
    • Wheeler JM, Knittle JD, Miller JD, Lupron Endometriosis Study Group: Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter double-blind randomized clinical trial. II. Assessment of safety. Am J Obstet Gynecol 169:26-33, 1993
    • (1993) Am J Obstet Gynecol , vol.169 , pp. 26-33
    • Wheeler, J.M.1    Knittle, J.D.2    Miller, J.D.3
  • 24
    • 0025685433 scopus 로고
    • Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analogue: Endocrine and clinical results
    • Venturini PL, Anserini P, Fasce V, et al: Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analogue: endocrine and clinical results. Fertil Steril 54:1021-1027, 1990
    • (1990) Fertil Steril , vol.54 , pp. 1021-1027
    • Venturini, P.L.1    Anserini, P.2    Fasce, V.3
  • 25
    • 0026772450 scopus 로고
    • Goserelin (Zoladex) depot in the treatment of endometriosis
    • Reichel RP, Schweppe K-W, Zoladex Endometriosis Study Group: Goserelin (Zoladex) depot in the treatment of endometriosis. Fertil Steril 57:1197-1202, 1992
    • (1992) Fertil Steril , vol.57 , pp. 1197-1202
    • Reichel, R.P.1    Schweppe, K.-W.2
  • 26
    • 0026663472 scopus 로고
    • An open randomized comparative study of the effect of goserelin depot in the treatment of endometriosis
    • Shaw RW, Zoladex Endometriosis Study Team: An open randomized comparative study of the effect of goserelin depot in the treatment of endometriosis. Fertil Steril 58:265-272, 1992
    • (1992) Fertil Steril , vol.58 , pp. 265-272
    • Shaw, R.W.1
  • 27
    • 0027292330 scopus 로고
    • Zoladex (goserelin acetate implant) in the treatment of endometriosis: A randomized comparison with danazol
    • Rock JA, Truglia JA, Caplan RJ, Zoladex Endometriosis Study Group: Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomized comparison with danazol. Obstet Gynecol 82:198-205, 1993
    • (1993) Obstet Gynecol , vol.82 , pp. 198-205
    • Rock, J.A.1    Truglia, J.A.2    Caplan, R.J.3
  • 29
    • 0026810438 scopus 로고
    • The role of GnRH analogues in the treatment of endometriosis
    • Shaw RW: The role of GnRH analogues in the treatment of endometriosis. Br J Obstet Gynecol 99(suppl.):9-12, 1992
    • (1992) Br J Obstet Gynecol , vol.99 , Issue.SUPPL. , pp. 9-12
    • Shaw, R.W.1
  • 30
    • 0024380709 scopus 로고
    • Metabolic changes during medical treatment of endometriosis: Nafarelin acetate versus danazol
    • Burry KA, Patton PE, Illingworth DR: Metabolic changes during medical treatment of endometriosis: nafarelin acetate versus danazol. Am J Obstet Gynecol 160:1454-1461, 1989
    • (1989) Am J Obstet Gynecol , vol.160 , pp. 1454-1461
    • Burry, K.A.1    Patton, P.E.2    Illingworth, D.R.3
  • 31
    • 0024409020 scopus 로고
    • Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis
    • Valimaki M, Nilsson CG, Roine R, Ylikorkala O: Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. J Clin Endocrinol Metab 69:1097-1103, 1989
    • (1989) J Clin Endocrinol Metab , vol.69 , pp. 1097-1103
    • Valimaki, M.1    Nilsson, C.G.2    Roine, R.3    Ylikorkala, O.4
  • 32
    • 0025057244 scopus 로고
    • Effect of nafarelin versus danazol on lipids and calcium metabolism
    • Bergquist C: Effect of nafarelin versus danazol on lipids and calcium metabolism. Am J Obstet Gynecol 162:589-591, 1990
    • (1990) Am J Obstet Gynecol , vol.162 , pp. 589-591
    • Bergquist, C.1
  • 33
    • 0023886645 scopus 로고
    • A comparison of the effects of buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis
    • Dlugi AM, Rufo S, D'Amico JF, Seibel MM: A comparison of the effects of buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril 49:913-916, 1988
    • (1988) Fertil Steril , vol.49 , pp. 913-916
    • Dlugi, A.M.1    Rufo, S.2    D'Amico, J.F.3    Seibel, M.M.4
  • 34
    • 0025605407 scopus 로고
    • Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis
    • Ylikorkala O, Nilsson CG, Hirvonen E, Viinikka L: Evidence of similar increases in bone turnover during nafarelin and danazol use in women with endometriosis. Gynecol Endocrinol 4:251-260, 1990
    • (1990) Gynecol Endocrinol , vol.4 , pp. 251-260
    • Ylikorkala, O.1    Nilsson, C.G.2    Hirvonen, E.3    Viinikka, L.4
  • 35
    • 0027531984 scopus 로고
    • Impact of medical treatment of endometriosis on bone mass
    • Dawood MY: Impact of medical treatment of endometriosis on bone mass. Am J Obstet Gynecol 168:674-684, 1993
    • (1993) Am J Obstet Gynecol , vol.168 , pp. 674-684
    • Dawood, M.Y.1
  • 37
    • 0023741271 scopus 로고
    • The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism
    • Johansen JS, Riis BJ, Hassager C, et al: The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab 67:701-706, 1988
    • (1988) J Clin Endocrinol Metab , vol.67 , pp. 701-706
    • Johansen, J.S.1    Riis, B.J.2    Hassager, C.3
  • 38
    • 0023766048 scopus 로고
    • Reversible trabecular bone density loss following induced hypo-estrogenism with GnRH analogue buserelin in premenopausal women
    • Matta WH, Shaw RW, Hesp R, Evans R: Reversible trabecular bone density loss following induced hypo-estrogenism with GnRH analogue buserelin in premenopausal women. Clin Endocrinol (Oxf) 29:45-51, 1988
    • (1988) Clin Endocrinol (Oxf) , vol.29 , pp. 45-51
    • Matta, W.H.1    Shaw, R.W.2    Hesp, R.3    Evans, R.4
  • 39
    • 0024382414 scopus 로고
    • Cortical and trabecular bone mineral content in women with endometriosis: Effect of gonadotropin-releasing hormone agonist and danazol
    • Dawood MY, Lewis V, Ramos J: Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin-releasing hormone agonist and danazol. Fertil Steril 52:21-26, 1989
    • (1989) Fertil Steril , vol.52 , pp. 21-26
    • Dawood, M.Y.1    Lewis, V.2    Ramos, J.3
  • 40
    • 0024391190 scopus 로고
    • Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma
    • Waibel-Treber S, Minne HW, Scharla SH, et al: Reversible bone loss in women treated with GnRH-agonists for endometriosis and uterine leiomyoma. Hum Reprod 4:384-388, 1989
    • (1989) Hum Reprod , vol.4 , pp. 384-388
    • Waibel-Treber, S.1    Minne, H.W.2    Scharla, S.H.3
  • 41
    • 0024790881 scopus 로고
    • A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis
    • Stevenson JC, Lees B, Gardner R, Shaw RW: A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis. Horm Res 32:161-163, 1989
    • (1989) Horm Res , vol.32 , pp. 161-163
    • Stevenson, J.C.1    Lees, B.2    Gardner, R.3    Shaw, R.W.4
  • 42
    • 0025072407 scopus 로고
    • The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis
    • Whitehouse RW, Adams JE, Baucroff K, et al: The effects of nafarelin and danazol on vertebral trabecular bone mass in patients with endometriosis.. Clin Endocrinol (Oxf) 33:365-373, 1990
    • (1990) Clin Endocrinol (Oxf) , vol.33 , pp. 365-373
    • Whitehouse, R.W.1    Adams, J.E.2    Baucroff, K.3
  • 43
    • 0025771969 scopus 로고
    • Gonadotropin-releasing hormone agonist therapy and its effect on bone mass
    • Nencioni T, Penotti M, Barbieri-Carones M, et al: Gonadotropin-releasing hormone agonist therapy and its effect on bone mass. Gynecol Endocrinol 5:49-56, 1991
    • (1991) Gynecol Endocrinol , vol.5 , pp. 49-56
    • Nencioni, T.1    Penotti, M.2    Barbieri-Carones, M.3
  • 44
    • 0026034221 scopus 로고
    • Bone mass in endometriosis patients treated with GnRH agonist implant or danazol
    • Dodin S, Lemay A, Maheux R, et al: Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 77:410-415, 1991
    • (1991) Obstet Gynecol , vol.77 , pp. 410-415
    • Dodin, S.1    Lemay, A.2    Maheux, R.3
  • 45
    • 0026065117 scopus 로고
    • Bone mineral density of the lumbar spine in women with endometriosis
    • Lane N, Baptista J, Orwoll E: Bone mineral density of the lumbar spine in women with endometriosis. Fertil Steril 55:537-542, 1991
    • (1991) Fertil Steril , vol.55 , pp. 537-542
    • Lane, N.1    Baptista, J.2    Orwoll, E.3
  • 48
    • 0028108330 scopus 로고
    • Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis
    • Uemura T, Mohri J, Osada H, et al: Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil Steril 62:246-250, 1994
    • (1994) Fertil Steril , vol.62 , pp. 246-250
    • Uemura, T.1    Mohri, J.2    Osada, H.3
  • 49
    • 0027942518 scopus 로고
    • Nafarelin therapy in endometriosis: Long-term effects on bone mineral density
    • Orwoll ES, Yuzpe AA, Burry KA, et al: Nafarelin therapy in endometriosis: long-term effects on bone mineral density. Am J Obstet Gynecol 171:1221-1225, 1994
    • (1994) Am J Obstet Gynecol , vol.171 , pp. 1221-1225
    • Orwoll, E.S.1    Yuzpe, A.A.2    Burry, K.A.3
  • 50
    • 0029981598 scopus 로고    scopus 로고
    • Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
    • Taga M, Minaguchi H: Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration. Acta Obstet Gynecol Scand 75:162-165, 1996
    • (1996) Acta Obstet Gynecol Scand , vol.75 , pp. 162-165
    • Taga, M.1    Minaguchi, H.2
  • 51
    • 0029871339 scopus 로고    scopus 로고
    • Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment
    • Paoletti AM, Serra GG, Cagnacci A, et al: Spontaneous reversibility of bone loss induced by gonadotropin-releasing hormone analog treatment. Fertil Steril 65:707-710, 1996
    • (1996) Fertil Steril , vol.65 , pp. 707-710
    • Paoletti, A.M.1    Serra, G.G.2    Cagnacci, A.3
  • 52
    • 0027257459 scopus 로고
    • Gonadotropin-releasing hormone agonists: Treatment of endometriosis
    • Barbieri RL: Gonadotropin-releasing hormone agonists: treatment of endometriosis. Clin Obstet Gynecol 36:636-641, 1993
    • (1993) Clin Obstet Gynecol , vol.36 , pp. 636-641
    • Barbieri, R.L.1
  • 53
    • 49749170890 scopus 로고
    • The use of newer progestins in the treatment of endometriosis
    • Kistner RW: The use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol 75:264-278, 1958
    • (1958) Am J Obstet Gynecol , vol.75 , pp. 264-278
    • Kistner, R.W.1
  • 54
    • 0023721919 scopus 로고
    • Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis
    • Luciano AA, Turksoy RN, Carleo J: Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 72:323-327, 1988
    • (1988) Obstet Gynecol , vol.72 , pp. 323-327
    • Luciano, A.A.1    Turksoy, R.N.2    Carleo, J.3
  • 55
    • 0017108903 scopus 로고
    • Endometriosis therapy with medroxyprogesterone acetate
    • Roland M, Leistein D, Kane R: Endometriosis therapy with medroxyprogesterone acetate. J Reprod Med 17:249-252, 1976
    • (1976) J Reprod Med , vol.17 , pp. 249-252
    • Roland, M.1    Leistein, D.2    Kane, R.3
  • 56
    • 0017226927 scopus 로고
    • Management of endometriosis with oral medroxyprogesterone acetate
    • Moghissi KS, Boyce CR: Management of endometriosis with oral medroxyprogesterone acetate. Obstet Gynecol 47:265-267, 1976
    • (1976) Obstet Gynecol , vol.47 , pp. 265-267
    • Moghissi, K.S.1    Boyce, C.R.2
  • 57
    • 0016694205 scopus 로고
    • Use of medroxyprogesterone acetate to prevent menopausal symptoms
    • Bullock JS, Massey FM, Gambrell RD: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 46:165-168, 1975
    • (1975) Obstet Gynecol , vol.46 , pp. 165-168
    • Bullock, J.S.1    Massey, F.M.2    Gambrell, R.D.3
  • 58
    • 0018820718 scopus 로고
    • Oral medroxyprogesterone in the treatment of postmenopausal symptoms
    • Schiff I, Tulchinsky D, Cramer D, Ryan KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. J Am Med Assoc 244:1443-1445, 1980
    • (1980) J am Med Assoc , vol.244 , pp. 1443-1445
    • Schiff, I.1    Tulchinsky, D.2    Cramer, D.3    Ryan, K.J.4
  • 59
    • 0020414881 scopus 로고
    • Effects of progestins on bone metabolism in postmenopausal women
    • Mandel FP, Davidson BJ, Erlik Y, et al: Effects of progestins on bone metabolism in postmenopausal women. J Reprod Med 27:511-514, 1982
    • (1982) J Reprod Med , vol.27 , pp. 511-514
    • Mandel, F.P.1    Davidson, B.J.2    Erlik, Y.3
  • 60
    • 0021353847 scopus 로고
    • Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women
    • Lobo RA, McCormick W, Singer F, Roy S: Depo-medroxyprogesterone acetate compared with conjugated estrogens for the treatment of postmenopausal women. Obstet Gynecol 63:1-5, 1984
    • (1984) Obstet Gynecol , vol.63 , pp. 1-5
    • Lobo, R.A.1    McCormick, W.2    Singer, F.3    Roy, S.4
  • 61
    • 0020071571 scopus 로고
    • A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles
    • Paterson MEL: A randomized double-blind cross-over trial into the effect of norethisterone on climacteric symptoms and biochemical profiles. Br J Obstet Gynecol 89:464-468, 1982
    • (1982) Br J Obstet Gynecol , vol.89 , pp. 464-468
    • Paterson, M.E.L.1
  • 62
    • 84942003745 scopus 로고
    • Treatment of postmenopausal hyperparathyroidism with norethindrone
    • Horowitz M, Wishart J, Need AG, et al: Treatment of postmenopausal hyperparathyroidism with norethindrone. Arch Intern Med 147:681-685, 1987
    • (1987) Arch Intern Med , vol.147 , pp. 681-685
    • Horowitz, M.1    Wishart, J.2    Need, A.G.3
  • 63
    • 0022387946 scopus 로고
    • Prevention of bone mineral loss in postmenopausal women by norethisterone
    • Abdalla HI, Hart DM, Lindsay R, et al: Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol 66:789-792, 1985
    • (1985) Obstet Gynecol , vol.66 , pp. 789-792
    • Abdalla, H.I.1    Hart, D.M.2    Lindsay, R.3
  • 64
    • 0026501267 scopus 로고
    • Hormone treatment of endometriosis: The estrogen threshold hypothesis
    • Barbieri RL: Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol 166:740-745, 1992
    • (1992) Am J Obstet Gynecol , vol.166 , pp. 740-745
    • Barbieri, R.L.1
  • 65
    • 0023973387 scopus 로고
    • Malignancy arising in endometriosis associated with unopposed estrogen replacement
    • Reimnitz C, E. B, Nieberg RK, Hacker NF: Malignancy arising in endometriosis associated with unopposed estrogen replacement. Obstet Gynecol 71:444-449, 1988
    • (1988) Obstet Gynecol , vol.71 , pp. 444-449
    • Reimnitz, C.1    E, B.2    Nieberg, R.K.3    Hacker, N.F.4
  • 66
    • 0028899915 scopus 로고
    • Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain
    • Hornstein MD, Yuzpe AA, Burry KA, et al: Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain. Fertil Steril 63:955-962, 1995
    • (1995) Fertil Steril , vol.63 , pp. 955-962
    • Hornstein, M.D.1    Yuzpe, A.A.2    Burry, K.A.3
  • 67
    • 0025272586 scopus 로고
    • Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogeterone acetate
    • Cedars MI, Lu JKH, Meldrum DR, Judd HL: Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogeterone acetate. Obstet Gynecol 75:641-645, 1990
    • (1990) Obstet Gynecol , vol.75 , pp. 641-645
    • Cedars, M.I.1    Lu, J.K.H.2    Meldrum, D.R.3    Judd, H.L.4
  • 68
    • 0030027358 scopus 로고    scopus 로고
    • Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis
    • Makarainen L, Ronneberg L, Kauppila A: Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis. Fertil Steril 65:29-34, 1996
    • (1996) Fertil Steril , vol.65 , pp. 29-34
    • Makarainen, L.1    Ronneberg, L.2    Kauppila, A.3
  • 69
    • 0025366431 scopus 로고
    • The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis
    • Surrey ES, Gambone JC, Lu JK, Judd HL: The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 53:620-626, 1990
    • (1990) Fertil Steril , vol.53 , pp. 620-626
    • Surrey, E.S.1    Gambone, J.C.2    Lu, J.K.3    Judd, H.L.4
  • 70
    • 0026726227 scopus 로고
    • Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: A prospective randomized trial
    • Surrey ES, Judd HL: Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J Clin Endocrinol Metab 75:558-563, 1992
    • (1992) J Clin Endocrinol Metab , vol.75 , pp. 558-563
    • Surrey, E.S.1    Judd, H.L.2
  • 71
    • 0028917615 scopus 로고
    • Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: The role of cyclic sodium ethidronate and low-dose norethindrone "add-back" therapy
    • Surrey ES, Voigt B, Fournet N, Judd HL: Prolonged gonadotropin-releasing hormone agonist treatment of symptomatic endometriosis: the role of cyclic sodium ethidronate and low-dose norethindrone "add-back" therapy. Fertil Steril 63:747-755, 1995
    • (1995) Fertil Steril , vol.63 , pp. 747-755
    • Surrey, E.S.1    Voigt, B.2    Fournet, N.3    Judd, H.L.4
  • 72
    • 0025334778 scopus 로고
    • Intermittent cyclic etidronate treatment of postmenopausal osteoporosis
    • Watts NB, Harris TS, Genant HK, et al: Intermittent cyclic etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79, 1990
    • (1990) N Engl J Med , vol.323 , pp. 73-79
    • Watts, N.B.1    Harris, T.S.2    Genant, H.K.3
  • 73
    • 0025366467 scopus 로고
    • Effect of intermittent cyclic etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
    • Storm T, Thamsborg G, Steiniche T, et al: Effect of intermittent cyclic etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271, 1990
    • (1990) N Engl J Med , vol.322 , pp. 1265-1271
    • Storm, T.1    Thamsborg, G.2    Steiniche, T.3
  • 74
    • 0025303668 scopus 로고
    • Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
    • Riis BJ, Christiansen C, Johansen JS, Jacobson J: Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J Clin Endocrinol Metab 70:920-924, 1990
    • (1990) J Clin Endocrinol Metab , vol.70 , pp. 920-924
    • Riis, B.J.1    Christiansen, C.2    Johansen, J.S.3    Jacobson, J.4
  • 75
    • 0026786746 scopus 로고
    • A randomized doubleblind placebo-controlled trial on the effects on bone metabolism of the combination of nafarelin acetate and norethisterone
    • Eldred JM, Haynes PJ, Thomas EJ: A randomized doubleblind placebo-controlled trial on the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. Clin Endocrinol (Oxf) 37:354-359, 1992
    • (1992) Clin Endocrinol (Oxf) , vol.37 , pp. 354-359
    • Eldred, J.M.1    Haynes, P.J.2    Thomas, E.J.3
  • 76
    • 0028232355 scopus 로고
    • Can hormone replacement therapy be used during medical therapy of endometriosis?
    • Edmonds DK, Howell R: Can hormone replacement therapy be used during medical therapy of endometriosis? Br J Obstet Gynecol 101:24-26, 1994
    • (1994) Br J Obstet Gynecol , vol.101 , pp. 24-26
    • Edmonds, D.K.1    Howell, R.2
  • 77
    • 0028860573 scopus 로고
    • Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogenprogestogen add-back therapy in the treatment of endometriosis
    • Kiilholma P, Korhonen M, Tuimala R, et al: Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogenprogestogen add-back therapy in the treatment of endometriosis. Fertil Steril 64:903-908, 1995
    • (1995) Fertil Steril , vol.64 , pp. 903-908
    • Kiilholma, P.1    Korhonen, M.2    Tuimala, R.3
  • 78
    • 4243691847 scopus 로고    scopus 로고
    • The efficacy of norethindrone acetate and conjugated equine estrogens combined with a gonadotropin releasing hormone agonist in the management of symptomatic endometriosis: A one-year multicenter trial
    • Surrey E, Hornstein MD, Weisberg G, et al: The efficacy of norethindrone acetate and conjugated equine estrogens combined with a gonadotropin releasing hormone agonist in the management of symptomatic endometriosis: a one-year multicenter trial. J Soc Gynecolog Investig 4:121A, 1997
    • (1997) J Soc Gynecolog Investig , vol.4
    • Surrey, E.1    Hornstein, M.D.2    Weisberg, G.3
  • 79
    • 0023078397 scopus 로고
    • Clinical profile of Org tibolone
    • Tax L, Goorissen EM, Kicovic PM: Clinical profile of Org tibolone. Maturitas 9:(suppl. 1):3-13, 1987
    • (1987) Maturitas , vol.9 , Issue.SUPPL. 1 , pp. 3-13
    • Tax, L.1    Goorissen, E.M.2    Kicovic, P.M.3
  • 80
    • 0023083159 scopus 로고
    • Longterm, placebo-controlled efficacy and safety study of Org tibolone in climacteric women
    • Benedek-Jaszmann LJ: Longterm, placebo-controlled efficacy and safety study of Org tibolone in climacteric women. Maturitas 9:(suppl. 1):25-33, 1987
    • (1987) Maturitas , vol.9 , Issue.SUPPL. 1 , pp. 25-33
    • Benedek-Jaszmann, L.J.1
  • 81
    • 0030061173 scopus 로고    scopus 로고
    • The effect of add-back treatment with tibolone (livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl)
    • Lindsay PC, Shaw RW, Bennink HJ, Kicovic P: The effect of add-back treatment with tibolone (livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). Fertil Steril 65:342-348, 1996
    • (1996) Fertil Steril , vol.65 , pp. 342-348
    • Lindsay, P.C.1    Shaw, R.W.2    Bennink, H.J.3    Kicovic, P.4
  • 82
    • 0031019505 scopus 로고    scopus 로고
    • Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis
    • Taskin O, Yalcinoglu AI, Kukuk S, et al: Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. Fertil Steril 67:40-45, 1997
    • (1997) Fertil Steril , vol.67 , pp. 40-45
    • Taskin, O.1    Yalcinoglu, A.I.2    Kukuk, S.3
  • 83
    • 0027716654 scopus 로고
    • Anabolic actions of parathyroid hormone on bone
    • Dempster DW, Cosman F, Parisien M, et al: Anabolic actions of parathyroid hormone on bone. Endocr Rev 14:690-709, 1993
    • (1993) Endocr Rev , vol.14 , pp. 690-709
    • Dempster, D.W.1    Cosman, F.2    Parisien, M.3
  • 84
    • 0027985064 scopus 로고
    • Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency
    • Finkelstein JS, Klibanski A, Schaefer EH, et al: Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N Engl J Med 331:1618-1623, 1994
    • (1994) N Engl J Med , vol.331 , pp. 1618-1623
    • Finkelstein, J.S.1    Klibanski, A.2    Schaefer, E.H.3
  • 85
    • 0029071351 scopus 로고
    • Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin
    • Roux C, Pellissier C, Listrat V, et al: Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporosis Int 5:185-190, 1995
    • (1995) Osteoporosis int , vol.5 , pp. 185-190
    • Roux, C.1    Pellissier, C.2    Listrat, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.